| REGENXBIO INC. DL-,0001 |
| USA |
| Gesundheit |
| US75901B1070 / A140E0 |
| RB0 (Frankfurt) / RGNX (NASDAQ) |
| FRA:RB0, ETR:RB0, RB0:GR, NASDAQ:RGNX |
| - |
| https://www.regenxbio.com.. |
|
Regenxbio Inc. is a leading clinical-stage biotechnology company focused on developing and commercializing gene therapies to treat genetic disorders through its proprietary NAV Technology Platform. This platform utilizes recombinant adeno-associated ..
>Volltext.. |
| 348.05 Mio. EUR |
| 374.02 Mio. EUR |
| 148.11 Mio. EUR |
| -126.51 Mio. EUR |
| -168.48 Mio. EUR |
| -3.26 EUR |
| 226.39 Mio. EUR |
| 29.95 Mio. EUR |
| -107.72 Mio. EUR |
| 1.95 |
| 80.28% |
| 24.75% |
| - |
| - |
| - |
| REGENXBIO |
| 30.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|